TrovaGene Inc  

(Public, NASDAQ:TROV)   Watch this stock  
Find more results for trov
0.868
+0.078 (9.87%)
After Hours: 0.880 +0.012 (1.38%)
Oct 18, 7:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.83 - 1.00
52 week 0.61 - 4.30
Open 0.93
Vol / Avg. 3.38M/789,228.00
Mkt cap 32.35M
P/E     -
Div/yield     -
EPS -1.20
Shares 37.27M
Beta 0.30
Inst. own 21%
Nov 7, 2017
Q3 2017 Trovagene Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 12, 2017
Trovagene Inc at Rodman & Renshaw Global Investment Conference
Aug 24, 2017
Trovagene Inc at Seaport Global Securities Southern California Investor Conference
Aug 9, 2017
Q2 2017 Trovagene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -7887.28% -10287.80%
Operating margin -7395.43% -10534.97%
EBITD margin - -10046.87%
Return on average assets -138.85% -67.95%
Return on average equity -455.16% -114.59%
Employees 53 -
CDP Score - -

Address

11055 Flintkote Ave
SAN DIEGO, CA 92121-1220
United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Officers and directors

Thomas H. Adams Jr. Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
William J. Welch Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Director
Age: 45
Bio & Compensation  - Reuters
Paul R. Billings M.D., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
John P. Brancaccio CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters